NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

Published:2020-04 Issue:4 Volume:18 Page:380-391
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Daly Mary B.¹,Pilarski Robert²,Yurgelun Matthew B.³,Berry Michael P.⁴,Buys Saundra S.⁵,Dickson Patricia⁶,Domchek Susan M.⁷,Elkhanany Ahmed⁸,Friedman Susan⁹,Garber Judy E.³,Goggins Michael¹⁰,Hutton Mollie L.¹¹,Khan Seema¹²,Klein Catherine¹³,Kohlmann Wendy⁵,Kurian Allison W.¹⁴,Laronga Christine¹⁵,Litton Jennifer K.¹⁶,Mak Julie S.¹⁷,Menendez Carolyn S.¹⁸,Merajver Sofia D.¹⁹,Norquist Barbara S.²⁰,Offit Kenneth²¹,Pal Tuya²²,Pederson Holly J.²³,Reiser Gwen²⁴,Shannon Kristen Mahoney²⁵,Visvanathan Kala¹⁰,Weitzel Jeffrey N.²⁶,Wick Myra J.²⁷,Wisinski Kari B.²⁸,Dwyer Mary A.²⁹,Darlow Susan D.²⁹

Affiliation:

1. 1Fox Chase Cancer Center;

2. 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

3. 3Dana-Farber/Brigham and Women’s Cancer Center;

4. 4St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

5. 5Huntsman Cancer Institute at the University of Utah;

6. 6Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

7. 7Abramson Cancer Center at the University of Pennsylvania;

8. 8O'Neal Comprehensive Cancer Center at UAB;

9. 9FORCE: Facing Our Risk of Cancer Empowered;

10. 10The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

11. 11Roswell Park Comprehensive Cancer Center;

12. 12Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

13. 13University of Colorado Cancer Center;

14. 14Stanford Cancer Institute;

15. 15Moffitt Cancer Center;

16. 16The University of Texas MD Anderson Cancer Center;

17. 17UCSF Helen Diller Family Comprehensive Cancer Center;

18. 18Duke Cancer Institute;

19. 19University of Michigan Rogel Cancer Center;

20. 20University of Washington/Seattle Cancer Care Alliance;

21. 21Memorial Sloan Kettering Cancer Center;

22. 22Vanderbilt-Ingram Cancer Center;

23. 23Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

24. 24Fred & Pamela Buffett Cancer Center;

25. 25Massachusetts General Hospital Cancer Center;

26. 26City of Hope National Medical Center;

27. 27Mayo Clinic Cancer Center;

28. 28University of Wisconsin Carbone Cancer Center; and

29. 29National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations;Gynecologic Oncology;2024-10

2. Predicting BRCA mutation and stratifying targeted therapy response using multimodal learning: a multicenter study;Annals of Medicine;2024-09-11

3. Implications of genetic testing and informed consent before and after genetic testing in individuals with cancer;World Journal of Clinical Oncology;2024-08-24

4. The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design;Epidemiology;2024-08-06

5. Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants;Gynecologic Oncology;2024-08